First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

drugs.com - 03/Jul 04:07

GAITHERSBURG, Md., July 02, 2024. artesian Therapeutics, Inc. (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell...

Cartesian Therapeutics doses first patient in phase 2 clinical trial of Descartes─08 to treat systematic lupus erythematosus

pharmabiz.com - 00:00

Cartesian Therapeutics, Inc, a clinical─stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first...

Syneos Health - USA: Research Nurse- Boise, Idaho

pharmiweb.com - 25/Jun 00:00

Competitive: Syneos Health - USA: Research Nurse Illingworth Research Group provides a range of patient focused clinical services to the...

Syneos Health - USA: Research Nurse - Saginaw, Michigan

pharmiweb.com - 30/Jun 00:00

Competitive: Syneos Health - USA: Research Nurse Illingworth Research Group provides a range of patient focused clinical services to the...

Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study

zacks.com - 27/Jun 14:26

Beam Therapeutics (BEAM) doses the first patient in a phase I/II study, evaluating in vivo base editor BEAM-302 for treating alpha-1 antitrypsin...

How ChatGPT is Transforming Cancer Care

unite.ai - 24/Jun 17:12

In recent years, the blend of artificial intelligence and healthcare has led to exciting advancements in cancer care. At the core of this change is...

Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor

drugs.com - 20/Jun 03:06

DUBLIN, June 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2b clinical trial...

KalVista initiates KONFIDENT-KID trial for on-demand treatment of HAE attacks with sebetralstat in children aged 2 to 11

haei.org - 27/Jun 06:40

KalVista initiates KONFIDENT-KID trial for on-demand treatment of hereditary angioedema attacks with sebetralstat in children aged 2 to 11 KalVista...

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

drugs.com - 22/Jun 04:06

OSAKA, Japan and CAMBRIDGE, Massachusetts, June 22, 2024 – Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b,...

Sarepta Therapeutics Announces Expanded US FDA Approval of Elevidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above

drugs.com - 20/Jun 23:06

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 20, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare...

Rubriques :